Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2021 Sep 28:10.1158/1055-9965.EPI-21-0644. doi: 10.1158/1055-9965.EPI-21-0644

Table 5b:

Factors associated with misclassification of peripheral neuropathy among males (N=1,497)

FP (N=79)1 FN (N=81)2

PRR1 95% CI P- value PRR1 95% CI P-value

Race

 White Ref Ref

 Black 0.59 0.27–1.30 0.191 1.71 0.78–3.79 0.183

 Others 0.00 0.00 1 0.00 0.00 1

Ethnicity

 Hispanic 1.31 0.15–11.35 0.807 NA

 Non-Hispanic Ref Ref

Smoking status

 Current 2.38 1.40–4.03 0.001 0.93 0.43–1.97 0.841

 Former 1.36 0.74–2.51 0.328 1 0.46–2.21 0.991

 Never Ref Ref

Current risky drinking

 Yes 0.95 0.41–2.20 0.911 1.24 0.41–3.79 0.703

 No Ref Ref

Obesity

 Yes 1.33 0.84–2.10 0.22 1.37 0.76–2.47 0.293

 No Ref Ref

Anxiety

 Yes 0.98 0.50–1.90 0.95 0.56 0.21–1.55 0.266

 No Ref Ref

Depression

 Yes 1.13 0.62–2.06 0.69 1.8 0.81–4.03 0.151

 No Ref Ref

Somatization

 Yes 5.26 3.06–9.04 <.001 1.8 0.82–3.95 0.141

 No Ref Ref

Full scale IQ 3

 Yes 2.69 0.87–8.29 0.086 2.08 0.56–7.67 0.272

 No Ref Ref

Pain in legs in past 4 weeks

 Yes 2.32 1.45–3.71 <.001 1.44 0.77–2.67 0.254

 No Ref Ref

Pain in hands/arms in the past 4 weeks

 Yes 0.94 0.52–1.69 0.84 0.93 0.42–2.07 0.862

 No Ref Ref Ref Ref

Age at assessment (yrs) 1.02 0.99–1.04 0.212 1.05 1.01–1.08 0.011

Age at diagnosis (yrs) 1 0.96–1.04 0.999 1 0.95–1.06 0.885
1

FP: False positive (self-report (endorsing≥2 symptoms) confirmed either PSN or PMN, but clinically it was not ascertained).

2

FN: False Negative (self-report did not confirm either PSN or PMN (endorsing ≥2 symptoms) but clinically it was ascertained).

3

Impairment defined as z scores ≤−2.

<: less than; CI: Confidence Interval; FN: False Negative; FP: False Positive; IQ: Intelligence Quotient; N: number; NA: not applicable; P: probability; PRR: Prevalence Rate Ratio; Ref: reference; yr: year; yrs: years